Nav: Home

NLST follow up reaffirms that low dose CT reduces lung cancer mortality

July 01, 2019

Denver--July 1, 2019--Early detection and treatment through screening with low-dose computed tomography (LDCT) has been investigated as a potential means of reducing lung cancer deaths for more than two decades. In 2011, a large U.S. study, the randomized National Lung Screening Trial (NLST), reported a significant 20% reduction in lung cancer mortality in high-risk current and former smokers screened annually for three years with LDCT as compared to chest x-rays. The NLST study included 26,722 patients in the LDCT arm and 26,730 in the x-ray arm at 33 medical institutions in the United States.

Now, in the Journal of Thoracic Oncology, the authors of the NLST research report on an extended analysis of the patient cohort that was followed up on after the 2011 study was published. The authors report that their original findings have been sustained.

This follow up study also supports and reaffirms findings from the NELSON Trial, which found a 26% reduction in lung cancer mortality in men and a 39% reduction in women. The NELSON research was reported at the International Association for the Study of Lung Cancer's 2018 World Conference on Lung Cancer in Toronto.

The NLST study randomized high-risk current and former smokers to three annual screens with either low dose computed tomography (LDCT) or chest radiographs (CXR) and demonstrated a significant reduction in lung cancer mortality in the LDCT arm after median 6.5 years follow-up. In this latest report, lead researcher Paul Pinsky, Ph.D., from the National Cancer Institute, part of the National Institutes of Health, in Bethesda, Md., and his team extended the follow up to 11.3 years for incidence and 12.3 years for mortality.

The study authors wrote that with an additional six years of mortality follow up, researchers could better understand if low dose CT screening prevented deaths from lung cancer, or merely delayed them. They report that the extended follow up did allow them to determine that LDCT did, in fact, prevent lung cancer deaths or at least delayed them for more than a decade.

"Lung cancer is the leading cause of cancer death worldwide and early detection and treatment through screening with low-dose computed tomography has been investigated as a potential means of reducing lung cancer deaths for more than two decades. This study adds further weight to the notion that CT screening is effective," said Dr. Pinsky.

The original report in 2011 found that 320 patients would have to be screened to prevent one death from lung cancer while the current follow up research found that 303 patients would have to be screened to prevent one lung cancer death.

This study reaffirms previously published research that shows screening patients at high risk for lung cancer can reduce lung cancer mortality.
-end-
About the JTO

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.

International Association for the Study of Lung Cancer

Related Lung Cancer Articles:

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
Air pollution is associated with cancer mortality beyond lung cancer
A large scale epidemiological study associates some air pollutants with kidney, bladder and colorectal cancer death.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Clint Smith
The killing of George Floyd by a police officer has sparked massive protests nationwide. This hour, writer and scholar Clint Smith reflects on this moment, through conversation, letters, and poetry.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Nina
Producer Tracie Hunte stumbled into a duet between Nina Simone and the sounds of protest outside her apartment. Then she discovered a performance by Nina on April 7, 1968 - three days after the assassination of Dr. Martin Luther King Jr. Tracie talks about what Nina's music, born during another time when our country was facing questions that seemed to have no answer, meant then and why it still resonates today.  Listen to Nina's brother, Samuel Waymon, talk about that April 7th concert here.